«This is an unbiased approach to combining the maximum possible data and comparing
a large number of drugs rather than one versus a select handful, so there's much more confidence in these findings,» says Dr. Parikh.
Research led by scientists at the University of Birmingham shows more precisely how G protein - coupled receptors, which are the key target of
a large number of drugs, work.
«We wanted to see whether very - large - scale screening across a diverse collection of cancer cell lines and
a large number of drugs could yield new combinations for patients with cancer,» says Adam Friedman, MD, PhD, of the CBRC and the MGH Cancer Center, who led the study.
A large number of drugs used today originate from nature.
We have the highest percentage of «Christians» in this nation with the largest prison population,
the larger number of drug users and that is a nation divided over religion because of god fearing Christians who believe in this wondrous loving god that gives little girls cancer to test the faith of her parents as they watch her dying.
That makes it relatively simple to gauge the effectiveness of
large numbers of drug candidates in treating a condition caused by a particular mutation.
Not exact matches
Since then, the film argues, a variety
of measures — from Jim Crow laws to President Richard Nixon's «war on
drugs» and President Bill Clinton's «three - strikes - you're - out» legislation — have served to send increasingly
large numbers of black men in prison, and several legal scholars and activists interviewed on camera suggest a profit motive at work, as well as racism.
Topics included: early reporting on inaccuracies in the articles
of The New York Times's Judith Miller that built support for the invasion
of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke
of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow
of the pilot who replaced him; an article published throughout the world that highlighted the West's lack
of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the
largest number of European civilian deaths since World War II; several investigations
of allegations by former members concerning the practices
of Scientology; corruption in the leadership
of the nation's
largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic
of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record
of far more serious transgressions; a look at the practices and values
of top Democratic operative and the clients they represent when out
of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy
of various proposed solutions to the failed war on
drugs; the poor - quality televised news program for teens (with lots
of advertising) that has quietly seeped into many
of America's public schools; an early exploration
of deceptive practices by the credit card industry; a study
of ecosystem destruction in Irian Jaya, one
of the world's last substantial rain forests.
As Fusion notes, «the nootropics community is surprisingly
large and involved,» with a
number of online forums offering recipes and information on users»
drugs of choice.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a
larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the
number of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In the last 10 years, a
large number of twin and multiple births are attributed to fertility treatments including fertility
drugs and in vitro fertilization.
Other factors that may lead to fetal distress during pregnancy and labor include an advanced maternal age,
drug or alcohol use, diabetes and a
large number of prior deliveries.
When Chicago citizens were asked about the parks during five community forums convened by the Mayor «s
Drug and Gang Task Force, the
largest number of negative comments by far were about the district «s failure to make its programs known to the public.
When City Councilman Daniel Dromm (D - Jackson Heights) criticized Mayor Michael Bloomberg's administration for the
large number of marijuana possession arrests made on his watch and advocated for legalizing medical marijuana, he said he was not dismissing the
drug's ill effects.
The nation's
largest pharmacy benefit manager, Express Scripts, will soon limit the
number and strength
of opioid
drugs prescribed to first - time users as part
of a wide - ranging effort to curb an epidemic affecting millions
of Americans.
Drug - delivery devices that flag nonsensical
number entry could prevent a
large fraction
of hospital - based errors and perhaps deaths.
Very
large numbers of eggs (28 - 33) were retrieved and they underwent many more rounds
of treatment (up to 10) with fertility
drugs than is common practice.
In the March 19, 2004, issue
of Science — dedicated to
drug discovery — Phil Szuromi, Valda Vinson, and Eliot Marshall wrote: «In recent years, the number of new drugs approved annually by the U.S. Food and Drug Administration has at best stayed steady, despite large increases in R&D investment.&ra
drug discovery — Phil Szuromi, Valda Vinson, and Eliot Marshall wrote: «In recent years, the
number of new
drugs approved annually by the U.S. Food and
Drug Administration has at best stayed steady, despite large increases in R&D investment.&ra
Drug Administration has at best stayed steady, despite
large increases in R&D investment.»
A statin
drug commonly used to lower cholesterol is not effective in reducing the
number and severity
of flare ups from chronic obstructive pulmonary disease (COPD), according to the results
of a
large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director
of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA..
Tissue engineers have been unable to grow epidermis with the functional barrier needed for
drug testing, and have been further limited in producing an in vitro (lab) model for
large - scale
drug screening by the
number of cells that can be grown from a single skin biopsy sample.
«Additional studies are needed to assess the effects
of those
drugs, with
larger numbers of treated and untreated patients as well as individuals who do not have Parkinson's.»
But most Africans with HIV claim never to use
drugs, engage in prostitution, or have
large numbers of sexual partners.
A
large number of these companies are clustered in Toronto, Montreal, Vancouver, Ottawa, and Saskatoon and provide a significant
number of drug discovery jobs in those areas.
The system can yield dose - response curves for candidate
drugs, screen the phenotypes
of large numbers of gene mutations, or execute complex custom protocols for completely new experiments.
But a new study finds that just a few resistant mutants can protect
large numbers of normal bacteria that would have been thought to be susceptible to the
drug therapy.
The nanopores can be filled with specific cytokines, oligonucleotides,
large protein antigens, or any variety
of drugs of interest to allow a vast
number of possible combinations to treat a range
of infections.
An innovative technique that quickly produces
large numbers of structurally related compounds is changing the way
drugs are discovered
Analyzing
large numbers of cells, each with slight differences in their DNA, for their ability to carry out a behavior or survive a
drug treatment can reveal the importance
of particular genes, or sections
of genes, in those abilities.
«Despite strong evidence against the use
of codeine in children, the
drug continues to be prescribed to
large numbers of them each year,» said Sunitha Kaiser, MD, UCSF assistant clinical professor
of pediatrics at UCSF Benioff Children's Hospital San Francisco and lead author.
While the incidence
of highly
drug - resistant tuberculosis in the United States is still negligible, the disease is gaining ground in countries where
large numbers of people have immune systems weakened by HIV.
He notes that the strategy opens up the possibility
of repurposing a
large number of existing
drugs for PKD therapy.
The
number of surgical procedures and
drugs prescribed to treat and prevent cardiovascular disease has risen substantially over the past two decades, and in 2012 - 13 the NHS spent just under # 7 billion in England alone on cardiovascular disease, the
largest chunk
of which was spent on hospital care.
The test called SkimuneTM, which is trademarked and has a patent pending, has been successfully tested by a
number of large pharmaceutical companies on
drugs in development and provides a reliable result within two weeks.
Robert Beall becomes CEO
of the CFF and, grasping the limitations
of gene therapy, invests $ 3.2 million in Aurora Biosciences Corp., where cell physiologist Paul Negulescu begins to look for a chemical cure using high - throughput methods to test
large numbers of potential
drugs.
Antibiotics also are responsible for the
largest number of medication - related adverse events and the cause
of about one in five visits to emergency departments for adverse
drug reactions.
In recent years, the
number of new
drugs approved annually by the U.S. Food and
Drug Administration has at best stayed steady, despite
large increases in R&D investment.
«Rapid access to
large quantities
of neurons will be useful for testing a significant
number of pharmacological
drugs in order to identify those capable
of preventing the death
of motor neurons,» concludes Cécile Martinat.
St. Michael's was the only site outside
of the United States involved in the Phase 2 clinical trial for the
drug and had the
largest number of patients enrolled in the Phase 3 trial.
In a presentation
of early clinical trial data to the 20th Annual Scientific Meeting
of the Society for Neuro - Oncology, physician scientists from the University
of New Mexico Comprehensive Cancer Center reported that a
large number of study participants responded well to the
drug combination.
Older adults who died from cancer had the
largest increase in the
number of drugs.
take a lead in developing the next generation
of cancer cell lines and use cell lines to systematically explore in vitro sensitivity to
large numbers of anticancer
drugs and
drug combinations in order to inform choice
of cancer types for early
drug trials.
The application
of Dr. Snyder's techniques has enhanced the development
of new agents in the pharmaceutical industry by enabling rapid screening
of large numbers of candidate
drugs.
Using good quality data from a
large number of people, the experienced scientists conducting this research found that people who took certain types
of arthritis
drugs had a lower risk
of dementia than people not taking this treatment.
As potential lead
drug candidates, we generated a
large number of derivatives
of the curry spice curcumin, which is effective in AD transgenic mice [8, 9].
In the search for compounds that might alter a protein's behavior or function — such as that
of alpha - synuclein —
drug companies often rely on so - called target - based screens that test the effect
large numbers of compounds have on the protein in question in rapid, automated fashion.
Because this idea was so attractive to researchers studying brain diseases, a
large number of potential
drugs were developed by pharmaceutical companies that block glutamate receptors, including mGluR5.
Our plant technology allows us to provide a cost - effective production solution for
drugs needed in
large quantities due to the
number of people affected by disease and / or high dosage requirements.
Normally, a phase 2 study is conducted in a slightly
larger number of people, with the goal
of collecting a little bit
of evidence that the
drug may work.
There have been a
number of challenges with these new
drugs, and they haven't really made it to phase three clinical trials, and so the reason is that it's very difficult to develop very specific inhibitors, because there is a
large family
of these phosphatases and it's difficult to ensure a specificity
of your
drug.
We are applying it to evaluate
large number of potential
drug targets in a faster and more systematic way than before and to select the best ones to work on.